Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, November 2009, p. 4903-4906, Vol. 53, No. 11
0066-4804/09/$08.00+0 doi:10.1128/AAC.00640-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Frédéric Coslédan,2,
Anne Robert,3 and
Bernard Meunier2*
UMR 5244 CNRS-UPVD-EPHE, Laboratoire de Biologie et d'Ecologie Tropicale et Méditerranéenne, Université de Perpignan, 52 avenue Paul Alduy, 66860 Perpignan, France,1 Palumed, 3 rue de l'Industrie, 31320 Castanet, France,2 Laboratoire de Chimie de Coordination du CNRS, 205 route de Narbonne, 31077 Toulouse cedex 4, France3
Received 12 May 2009/ Returned for modification 10 June 2009/ Accepted 1 July 2009
We report the in vitro activities of trioxaquines against larval and adult-stage schistosomes at 5 and 50 µg/ml, respectively. Such activities are equivalent to that of praziquantel, the major and rather unique drug currently used for the treatment of schistosomiasis. In this range of concentrations, artemisinin derivatives (artesunate and artemether) have no activity.
Published ahead of print on 13 July 2009.
Major contributors to this work.
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»